Press release from Acarix AB (publ) 2018-04-23
Acarix publishes the annual report for 2017
Today, Monday April 23, Acarix is publishing its Annual Report for 2017 on the company website www.acarix.com.
The Annual Report is also attached to this press release.
For further information please contact:
Christian Lindholm, Interim CEO
E-mail: secli@acarix.com
Phone: +46 705 118333
This information is information that Acarix AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation 596/2014. The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CET on 23 April 2018.
Notes to editors:
Acarix was established in 2009, and since 2010 investors Sunstone Life Science Ventures (DK) and SEED Capital (DK) have supported it towards market introduction. Acarix was listed on Nasdaq First North Premier in 2016 and has attracted a highly-experienced management team.
The Acarix CADScor®System combines ultra-sensitive acoustic detection of turbulent arterial flow and myocardial movement with advanced algorithms in a portable device to provide a patient-specific score to non-invasively assess the risk for Coronary Artery Disease (CAD) in less than 10 minutes. The system has been clinically validated.
See more at www.acarix.com. Acarix_Annual Report_2017
PR_Acarix Annual Report 2017
—
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Acarix AB via Globenewswire
